Medicilon has been listed in the "2022 China Biopharmaceutical Innovation Billboard"

BOSTON - June 6, 2023 - PRLog -- The China Biopharmaceutical Industry Chain Innovation Transformation Summit and the 3rd China Biopharmaceutical Innovation Billboard Awards Ceremony were grandly opened in Nanjing, China.

Shanghai Medicilon Inc (Medicilon) stands out among many CROs in the country by virtue of advanced R&D technology, innovative service platform, outstanding performance and excellent market reputation, as a result, Medicilon is awarded the "Golden Horse Award - 2022 Best Preclinical CRO/CDMO Enterprise."

About Medicilon
Medicilon is an integrated contract research organization (CRO), providing comprehensive one-stop new drug R&D services for pharmaceutical enterprises and scientific research institutions around the world.

Based on key links of drug R&D, we focus on the demand for innovation and the development of the global pharmaceutical industry. With our experience in serving domestic and foreign biomedical industries, we have built an integrated technical platform covering key technologies in drug discovery, pharmaceutical research, and preclinical research, in a bid to provide comprehensive preclinical new drug R&D for the global biomedical industry.

(https://www.medicilon.com/)